


Immuno-Oncology: The Cancer Immunotherapy Revolution Has Just Begun

Why do some cancer patients respond to immunotherapy and others don't?

Evotec immunologists have the knowledge and the experience to support your immuno-oncology projects from target identification to the clinic either as part of an integrated project or at any pivotal step(s) of your project where our expertise will perfectly synergize with yours to make a difference.

- ▶ We support cancer immunotherapy programs throughout the discovery journey and up to the immunomonitoring of patients
- ▶ In-depth immunology expertise from innate to adaptive immunity
- ▶ Proven experience with multiple therapeutic modalities: small molecules, biologics, cancer vaccines, ASO, RNA and cell therapy
- ▶ Genetic engineering of primary immune cells for optimal target validation
- ▶ Development of bespoke *in vitro* immunological assays
- ▶ Assessment of immunotherapies at the single cell level, utilizing analysis of the immunological synapse
- ▶ Syngeneic and humanized preclinical mouse models dedicated to immuno-oncology
- ▶ Access to cancer patient samples for translational validation of immunotherapies
- ▶ Development of biomarkers strategies early on in discovery projects (e.g. whole blood assays)
- ▶ Integrating technologies across disciplines de-risking your strategy





Evotec's experienced immuno-oncology team supports discovery projects from target identification to designing immunomonitoring strategies for Phase I clinical trials. Leveraging expertise in immunology, diverse therapeutic modalities, and advanced technology platforms, we address your cancer immunotherapy challenges.

Our success lies in identifying the best strategies for specific targets or cancer indications and integrating biomarker knowledge early to enhance disease understanding. Additionally, our network of clinicians provides access to relevant cancer patient samples, reducing risks and improving the validation of lead candidates in a translational fashion. This is filling a key gap in immunotherapeutics discovery thus supporting a smoother progression to the clinic.

Functional *in vitro* immunological assays

- ▶ Supporting small molecules, biologics and cell therapy programs
- ▶ T-cells ($\alpha\beta$ & $\gamma\delta$), Treg, NK cells, B-cells, Neutrophils, M1/M2, Dendritic Cells, MDSCs
- ▶ Proliferation, cytokines production, killing, tracking of surface markers, suppression assay

Visualizing immune cells "in action" at the contact of tumour cells


- ▶ Evaluation of IO products at the single-cell level monitoring immunological synapse
- ▶ Quantification of the data using Metamorph software
- ▶ High-speed imaging of the immunological synapse (ImageStream X)
- ▶ 384w plate assays with high-throughput confocal imager: Operetta

Preclinical *in vivo* rodent models in immuno-oncology

- ▶ Syngeneic tumour models and human xenograft models with humanized mice
- ▶ Therapeutic efficacy, PK/PD, analyse of the TME, *ex vivo* functional assays

Filling the gap in drug discovery by accessing cancer patient samples

- ▶ Complex flow-cytometry based analyses on fresh human tumour resections, gene signature
- ▶ Functional assay on blood, e.g. for target engagement validation
- ▶ Additional technologies for identification of biomarkers, e.g. Functional assay on blood, e.g. scRNAseq, TCR sequencing, proteomics, metabolomics



NK cell killing leukemia cells

Contact us to speak to one of our immunologists to see how we can progress your projects. Visit our immuno-oncology pages to learn more